why choose us

300×250 Ad Slot

Research Article: Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study

Date Published: 2023-07-25

Introduction:
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, the third leading cause of cancer-related death and % of HCC cases were attributable to chronic HBV infection, but the majority of cases occurred particularly in East Asia. , More than % of HCC patients are diagnosed with intermediate or advanced stage disease. , Lenvatinib (LEN) is one of the first-line treatments for advanced HCC and is also recommended for some intermediate HCC. However, efficacy of targeted treatment alone including by…

Read more

300×250 Ad Slot